Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

235.25 7.93 +3.49%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC 10-Q filed Nov 2, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 2, 2026 · accepted 4:09 PM ET · Document on sec.gov · Filing index

Red flags

Share dilution Nov 2, 2026
Shares outstanding rose 5.6% in a year, to 64.2 million

10-Q filed Nov 2, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 51 added · 33 removed · 88 modified; 6 with only figures updated

Jazz Pharmaceuticals PLC 10-Q filed Nov 2, 2026

Red flags

What changed

Stockrow Weekly